Prescribing advice for the management and treatment of psoriasis
|
|
- Sharyl Reed
- 8 years ago
- Views:
Transcription
1 Prescribing advice for the management and treatment of psoriasis This guidance contains suggested advice for the management and treatment of patients presenting with psoriasis. This guidance applies to Camden primary care practitioners (GPs, practice nurses, community nursing). It will also be relevant to community pharmacists both as assisting with patient education and suitable treatments. Start date: 11 th December 2006 Reviewed & updated: January 2013 Next Review Date: January 2015 Original agreed by: Camden PCT Dermatology Group on 7 th November 2006 & by Medicines Management, Interventional Procedures and Medical Devices Committee on 30 th November Updates approved by: NHS Camden Medicines Management Committee on 25/11/10, 08/07/11 and 27/02/13 Comments on this guidance should be directed to the Medicines Management Team, Camden Clinical Commissioning Group (CCG) by to mmt.camdenccg@nhs.net This document is for use by Camden Prescribers and primary care practitioner only the information contained in it is not suitable to be shared with patients / public or non NHS Organisations. Produced to inform and review local decision making using the best available evidence at the time of publication. The information in this document may be superseded in due course. Not to be used or reproduced for commercial or marketing purposes. Every care has been taken in the compilation and publication of this document, however, neither the Medicines Management Team nor Camden CCG will be held responsible for any loss, damage or inconvenience caused as a result of any inaccuracy or error within these pages. Please also note that Camden CCG is not responsible for the content or availability of any external sites to which it may include links. Please be aware that this information is correct at the time of the search and Camden CCG is under no obligation to inform you if the situation changes in the future. The information provided is the property of Camden CCG and is subject to Intellectual Property and Database Rights. Camden CCG does not restrict assessment, treatment, therapy or care on the basis of age, gender, ethnic group, sexual orientation or any other irrelevant consideration. Prescribing Advice for Psoriasis v 3 Page 1 of 10
2 1 SUMMARY Prescribing advice for the management and treatment of psoriasis 2 RESPONSIBLE PERSON: Neeshma Shah 3 ACCOUNTABLE DIRECTOR: David Cryer 4 APPLIES TO: NHS Camden Clinical Commissioning Group (CCG) primary care practitioners. 5 GROUPS/ INDIVIDUALS WHO HAVE OVERSEEN THE DEVELOPMENT OF THIS GUIDANCE 6 GROUPS WHICH WERE CONSULTED AND HAVE GIVEN APPROVAL: 7 EQUALITY IMPACT ANALYSIS COMPLETED: NHS Camden Clinical Commissioning Group (CCG) Medicines Management Team Camden Medicines Management Committee Guidance Screened 05 July 2013 Template completed 8 RATIFYING COMMITTEE(S) & DATE OF FINAL APPROVAL: Camden Medicines Management Committee 27 th February VERSION: V3 10 AVAILABLE ON: Intranet Camden GPs Website 11 RELATED DOCUMENTS: 12 DISSEMINATED TO: To be placed on intranet and disseminated via Prescribing Matters. 13 DATE OF IMPLEMENTATION: July DATE OF NEXT FORMAL REVIEW: January 2015 Prescribing Advice for Psoriasis v 3 Page 2 of 10
3 DOCUMENT CONTROL Date Version Action Amendments November Guidance first implemented March Guidance reviewed N/A November Guidance amended Addition of information and on Finger Tip Units including diagram. Addition of appendix on Drug Tariff topical treatments for psoriasis. July Guidance amended A cautionary note added to advise that aqueous cream should be used as a soap substitute only. Nail psoriasis advice re treatment has been expanded. July Guidance amended Bath emollients removed February Guidance amended Guidance updated following publication of NICE CG153 (The assessment and management of psoriasis). NICE general recommendations regarding treatment and assessment added. Advice updates to flexure and genital psoriasis, scalp psoriasis and facial psoriasis. Advice re topical calcineurin inhibitors added. Appendix on drug tariff topical treatments removed. Prescribing Advice for Psoriasis v 3 Page 3 of 10
4 Prescribing Advice for the management and treatment of psoriasis Initial assessment 1-8 There is no cure for psoriasis, although there are effective suppressive treatments aimed at inducing a remission or making the amount of psoriasis tolerable to the patient The clinician should make the patient aware of the possible therapeutic options, including the simplest available therapies and the option that treatment may not be necessary. The patient s perception of his or her disability will often dictate the need for treatment. Assess the impact of disease on physical, psychological and social wellbeing. To be able to advise the patient on suitable therapies, the clinician needs to know the sites, extent and severity of the psoriasis Assess the severity and impact of any type of psoriasis before referral. If referral is considered necessary, treatment should be initiated while awaiting a clinic appointment. Drugs thought to precipitate or worsen psoriasis include beta-adrenoceptor blocking drugs, NSAIDs, lithium, chloroquine, mepacrine and alcohol Discuss risk factors for cardiovascular co-morbidities with patients who have any type of psoriasis. Offer preventative advice, healthy lifestyle information and support for behavioural change to meet the needs of the individual where risk factors are identified. 8 Points to discuss/consider at initial presentation: o Explanation of psoriasis, including reassurance that it is neither infectious nor malignant o May need to prescribe a variety of emollients e.g. ointment + cream (see emollient recommendations below) or prescribe just one emollient depending on skin texture and extent of psoriasis. o Treatment options (including no active treatment) o The probable benefit the patient can expect from treatment. o Techniques of application of any topical treatment (especially important with dithranol and scalp preparations) o An introduction to patient support groups may be helpful e.g. The Psoriasis Association o Arrange a review appointment 4 weeks after starting new topical therapy in adults, and 2 weeks in children, to evaluate treatment response, adherence and tolerability 8 General recommendations for treatment 8 Offer topical therapy as first line treatment. If phototherapy or systemic therapy is required, refer the patient. When offering topical treatment take into account patient preference, cosmetic acceptability and practical aspects of application and the site(s) and extent of psoriasis to be treated. Lotion or solution formulations may be more suitable for the scalp or hair-bearing areas, ointments may be more suitable for areas with thick adherent scale. Where psoriasis has responded to topical treatment, discuss the importance of continuing treatment with the patient or in the case of topical corticosteroids, how long they should be used for. Where topical treatment has not been effective or only partly effective, consider possible nonadherence to treatment and reasons for this before considering an alternative treatment. This may include difficulties with application, cosmetic acceptability or tolerability. Patients should be supported to adhere to treatment 9. Treatment of chronic plaque psoriasis Emollients should be used regularly for all types of psoriasis to soften scaling, reduce any irritation 6 and help relieve other symptoms such as itch. 7 The NHS Camden prescribing recommendations for these are shown in the table below: Prescribing Advice for Psoriasis v 3 Page 4 of 10
5 Emollient Creams Step one Hydrous ointment (oily cream) Emollient Ointments Step one Emulsifying ointment White soft paraffin 50% liquid paraffin 50% (50/50) Step 2 Diprobase cream Cetraben cream Double base gel Oilatum cream Step 2 Hydromol ointment Epaderm ointment Soap substitutes All creams and ointments may be used as soap substitutes except 50/50. Aqueous cream- Should be used as a soap substitute only. Aqueous cream and emulsifying ointment are the most cost effective options for the cream and ointment respectively. Note there are significantly more skin reactions to the cream preserved with phenoxyethanol than to chlorocresol.(check with your local pharmacist) Bath additives Bath additives are not recommended as they are not cost-effective compared to soap substitutes and may be wasteful as a large proportion will be washed away during use, with bath/shower water. Patients should be warned that these are not a replacement for emollient creams and ointments and if purchased should be advised to take care to avoid slipping when stepping in and out of the bath. Routine use of antiseptic/ emollient combinations is not routinely recommended Recommended suitable quantities for prescribing The following is intended as a guide to help determine appropriate quantities of dermatological preparations to prescribe for adult patients. Children will require less. Emollients and non-steroid preparations 1 The following quantities are usually suitable for an adult for twice daily application for one week. Area of body Creams and ointments Lotions Face 15-30g 100ml Both hands 25-50g 200ml Scalp g 200ml Both arms or both legs g 200ml Trunk 400g 500ml Groin and genitalia 15-25g 100ml Corticosteroid preparations 1,2 The quantities below are the recommendation for adult patients where the preparation is used ONCE daily for two weeks. Children require less, for example, a child of 4 years will require one third of the adult quantity. Area of body Quantity for once daily application for 2 weeks Face and neck 15-30g Both hands 15-30g Scalp 15-30g Both arms 30-60g Both legs 100g Trunk 100g Groin and genitalia 15-30g Prescribing Advice for Psoriasis v 3 Page 5 of 10
6 Be aware that continuous use of potent or very potent corticosteroids may cause the following: Irreversible skin atrophy Psoriasis to become unstable Systemic side-effects when applied continuously to extensive psoriasis (more than 10% of the body surface area is affected) Aim for a four week break between courses of potent or very potent corticosteroids. Consider topical treatments that are not steroid-based (such as coal tar or vitamin D or vitamin D analogues) during this period 8. Offer a review at least annually to those using steroids to assess presence of steroid atrophy and other effects 8 Finger Tip Units When counselling patients on the appropriate doses and use of corticosteroid preparations, applying the Finger Tip Unit (FTU) measurement is a useful method of counselling patients on the appropriate quantities of cream or ointment to use. One FTU is equivalent to about 500 mg and is sufficient to treat a skin area about twice that of the flat of the hand with the fingers together. 1 The approximate amount that should be applied for each area of the body is shown below Prescribing Advice for Psoriasis v 3 Page 6 of 10
7 NHS Camden Prescribing Recommendations BEFORE USING THIS GUIDANCE ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Condition Drug choice Special considerations Chronic plaque psoriasis Flexure and genital psoriasis e.g. breasts, groin For all patients: Simple emollients should be used regularly for all patients (if patient untroubled by the condition) or treat with coal tar cream/lotion Short term treatment (to gain rapid improvement): Calcipotriol and potent topical steroid e.g. betamethasone valerate 0.1% or mometasone furoate 0.1% (as separate products) 12 hours apart (one in the morning, one in the evening) on the plaques OR Calcitrol ointment ONCE daily If patient has responded to calcipotriol and steroid, the combination product Dovobet (calcipotriol and betamethasone) may be used Steroids to be used short-term: usually 3-7 days duration (but no more than 4 weeks), and intermittently. Not suitable for widespread psoriasis. For long term treatment or if steroid not effective/partly effective after a maximum of 8 weeks treatment with choices above: Calcitrol ointment applied TWICE daily If calcitrol alone is not effective or not tolerated then consider: Coal tar cream, lotion or ointment OD or BD (see notes opposite) If treatment ineffective consider referral for treatment with short contact dithranol, very potent corticosteroids or tazarotene. Emollients should be offered to all patients and regular use encouraged 1 st line: Mild to moderate potency steroid e.g. hydrocortisone 1% (mild) or clobetasone butyrate 0.05% (moderate) or betamethasone valerate 0.025% (moderate) once or twice daily, for a maximum of 2-4 weeks. For longer term use or if moderate potency steroids are ineffective or corticosteroids cannot be used: Calcitrol ointment OD or BD OR Consider topical tacrolimus ointment BD for up to 4 weeks where there has been a poor response to steroids or steroid treatment is required for longer than 2 weeks. Topical tacrolimus can be considered but should be initiated by a specialist or on the recommendation of a specialist.. Topical tacrolimus or pimecrolimus for the management of psoriasis is not licensed. Calcitrol is less likely to cause irritation than calcipotriol 2,6. Calcipotriol ointment is more effective than the cream but patients may find that it preferable to use the cream version in the morning. Avoid using Calcipotriol on the face and flexures. Monitor for irritant effects when used on the limbs and body. Do not exceed max recommended weekly dose-see BNF or BNF-C (children s dosage). Treatment needs to be used for at least 6-8 weeks to see improvement. Palms and soles may need trial of potent steroids for 4 weeks. People with more extensive severe disease may require referral to secondary care for phototherapy or systemic biological treatments Coal tar- a wide variety of proprietary preparations are available (see BNF) Exorex lotion (coal tar 5%) Psoriderm Cream (coal tar 6%) Carbo-Dome cream (coal tar 10%) Sebco scalp ointment (Coal tar 12%, salicyclic acid 2%, precipited sulphur 4%) Note BP preparations of coal tar are likely to be available as specials ONLY and therefore of high cost Treatment duration with topical steroids usually limited to 2-4 weeks, or 1-2 weeks per month. Vitamin D derivatives can be irritant in the flexural areas, and this can limit their use, especially calcipotriol Calcitrol is less likely to cause irritation than calcipotriol Prescribing Advice for Psoriasis v 3 Page 7 of 10
8 Condition Drug choice Special considerations Coal tar products can be considered for intermittent use for flexural psoriasis. Use with caution in genital psoriasis Antifungal treatment should not be used unless there are signs of fungal infection (red to red-brown, sometimes itchy, flat or slightly raised plaques with active borders [pustules or vesicles]). Dithranol and topical retinoids are NOT recommended for flexural sites. Scalp psoriasis Potent or very potent steroids are NOT recommended for flexures and genitals as these areas are particularly vulnerable to steroid atrophy. Emollients should be offered to all patients to soften scale If scale is thick and adherent: Olive oil, coconut oil, or arachis oil, to soften scale. A keratolytic, such as salicylic acid combined with coal tar and coconut oil (Cocois, Sebco ). These may be rubbed into scalp at night and should be used prior to application of a topical steroid if this is also prescribed. For treatment of plaques: 1st line A potent topical steroid e.g. Betamethasone valerate 0.1% scalp application (such as Betacap ) applied to plaques by parting hair and rubbed in up to 4 weeks. OR Topical corticosteroid scalp preparation is licensed for use for up to 4 weeks only. Vitamin D scalp preparation may be more likely than a topical corticosteroid to cause local irritation. Use of this product alone can be considered for mild to moderate scalp psoriasis or where patients are intolerant or cannot use topical corticosteroids. Calcipotriol scalp application once daily for up to 8 weeks OR A combination steroid and calcipotriol product (Xamiol betamethasone 0.05% and calcipotriol 50mcg/g) can be considered once daily, for up to 4 weeks 2 nd line Consider very potent corticosteroid e.g. clobetasol propionate 0.05% shampoo BD for 2 weeks if 1 st line treatment not effective or unsatisfactory response. Coal tar preparations OD or BD (Polytar Liquid, Alphosyl 2 in 1, Capasal ). The use of coal tar preparations has a poor evidence base Coal tar based shampoos should not be used alone in severe psoriasis but may have a role in reducing itch in scalp psoriasis based on expert opinion Prescribing Advice for Psoriasis v 3 Page 8 of 10
9 Condition Drug choice Special considerations Facial psoriasis Guttate psoriasis Emollients should be offered to all patients and regular use encouraged 1 st line A mild or moderate topical steroid (e.g hydrocortisone 1%,(mild) or Clobetasone butyrate 0.05% (moderate), Betamethasone valerate 0.025%) (moderate) once or twice daily for a maximum of 2 weeks 2 nd line (if topical mild to moderate corticosteroid is not effective) consider: Calcitriol ointment OD or BD Treatment with a topical calcineurin inhibitor e.g. tacrolimus ointment can be considered but should be initiated by a specialist or on the recommendation of a specialist. Topical tacrolimus or pimecrolimus for the management of psoriasis is not licensed. In treating facial psoriasis, topical calcineurin inhibitors should be used for a maximum of 4 weeks. Potent or very potent steroids are NOT recommended for face 1 st line Emollients should be offered to all patients and regular use encouraged 2 nd line A moderate potency topical steroid e.g Clobetasone butyrate 0.05% (moderate), Betamethasone valerate 0.025%) (moderate) Calcipotriol or calcitriol cream/ointment Coal tar cream/ointment/lotion Topical steroids should be used for a maximum 2 weeks, or 1-2 weeks per month Calcipotriol may be considered if only applied to hair margins/ears but not to the face due to irritation, and not licenced for use on the face. No value of oral antibiotics Consider early referral for phototherapy Calcipotriol cream may be very difficult to apply to the very small plaques and therefore cause irritation to surrounding skin. Calcitriol could then be considered. Nail psoriasis For mild disease: Advise to keep nails short and conceal with nail vanish if required. Advise avoiding manicuring the cuticle and prosthetic nails For moderate to severe disease: As above Evidence to support the effectiveness of topical treatment is limited. Nail disease responds poorly to topical treatment. Topical corticosteroids, salicylic acid, calcipotriol or tazarotene used alone or in combination can be considered but preferably/only after specialist advice has been sought Refer to podiatry as appropriate if nails distorted/painful Check to see if there is a coexistent fungal infection as this may worsen the appearance. Topical treatments such as topical steroids, vitamin D analogues etc are not licensed for this indication and have very limited evidence base Notes Some products are formulated as combinations. These are usually more expensive than their separate constituents, but they may be useful where compliance is a problem. Some BP preparations may be difficult to obtain and if made as a special are likely to cost considerably more than a proprietary preparation. Advice on current costs can be obtained from a local community pharmacist. Prescribing Advice for Psoriasis v 3 Page 9 of 10
10 References and further reading 1. BNF 64 (September 2012) British National Formulary. 64th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. 2. NHS Clinical Knowledge Summaries ; 3. Smith CH, Barker JNWN (2006) Psoriasis and its management. British Medical J 333, British Association of Dermatologists. Psoriasis guideline British Association of Dermatologists and Primary Care Dermatology Society. Recommendations for the initial management of psoriasis (Reviewed Jan 2010) 6. SIGN. Diagnosis and management of psoriasis and psoriatic arthritis in adults. A national clinical guideline. October MeReC (1999) Using topical corticosteroids in general practice. MeReC Bulletin 10(6), NICE Clinical Guideline 153. The assessment and management of psoriasis. October NICE Clinical Guideline 76. Medicines Adherence: Involving patients in decisions about prescribed medicines and supporting adherence. January 2009 Comments on this guidance should be sent to the Medicines Management Team by to mmt.camdenccg@nhs.net Prescribing Advice for Psoriasis v 3 Page 10 of 10
TOPICAL TREATMENTS FOR PSORIASIS
TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you
More informationTreatment options a simple guide
Guide Treatment options a simple guide To decide which treatment is right for you, a good starting point is to know what options you have and to understand the pros and cons of each one. People respond
More informationPsoriasis Treatment Transition Pathway
Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways
More informationX-Plain Psoriasis Reference Summary
X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects
More informationNational Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.
VOLUME 6 NUMBER 6 2000 PSORIASIS National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.ie SUMMARY The aim of treatment is
More informationPsoriasis - suspected
Psoriasis - suspected Possible link to alcohol use, depression, other medications History and examination Consider referral to Health Trainers Consider differential diagnoses Is the patient systemically
More informationScalp Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
10672 SCALP0913 Scalp Psoriasis 12pp final_layout 1 11/10/2013 18:13 Page 2 Scalp Psoriasis A positive approach to psoriasis and psoriatic arthritis What are the aims of this leaflet? This leaflet has
More informationPSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis
PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly
More informationDepartment of Dermatology, Churchill Hospital PUVA Treatment
Oxford University Hospitals NHS Trust Department of Dermatology, Churchill Hospital PUVA Treatment information for patients CONTENTS What is PUVA 3 What conditions are treated with PUVA? 3 How is PUVA
More informationNail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What is psoriasis? Psoriasis (Ps) is a long-term (chronic) scaling disease of the skin, which affects 2% 3% of the UK population.
More informationEBMT Education Day for Nurses and AHPs April 2012 Skin care: not every rash is GVHD
EBMT Education Day for Nurses and AHPs April 2012 Skin care: not every rash is GVHD Eileen Parry Consultant Dermatologist Tameside Hospital Foundation Trust Overview How to assess a patient with a rash
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationPATIENT RESOURCES: PSORIASIS
PATIENT RESOURCES: PSORIASIS Psoriasis is a persistent skin disorder in which there are red, thickened areas with silvery scales, most often on the scalp, elbows, knees, and lower back. Some cases, of
More informationEfficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong
ORIGINAL ARTICLES Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong Drs. C. W. Fung, L.Y. Chong, C.Y. Leung, C. N. Look, K.K. Lo, K. M. Ho Social Hygiene Service
More informationScottish Medicines Consortium
Scottish Medicines Consortium betamethasone valerate 2.25mg medicated plaster (Betesil ) No. (622/10) Genus Pharmaceuticals 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGuidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies Alan Menter,
More informationDry skin, eczema, psoriasis and flare-ups
Dry skin, eczema, psoriasis and flare-ups Let s feel comfortable in our skin FL4368_1000031525 BTS LFGT Specialist Skin A5LFT 12pp V7.indd 1 21/02/2014 09:58 Some of us live with a dry or sore skin condition.
More informationTOPICAL TREATMENTS. for psoriasis NATIONAL PSORIASIS FOUNDATION. » Over-the-counter products» Combination agents» + more
NATIONAL PSORIASIS FOUNDATION TOPICAL TREATMENTS for psoriasis» Topical steroids» Vitamin D derivatives» Vitamin A derivatives» Over-the-counter products» Combination agents» + more Photo illustration
More informationTreating psoriasis and psoriatic arthritis. A booklet for patients and carers
Treating psoriasis and psoriatic arthritis A booklet for patients and carers Picture credits Cover Stuart Neville Page 4 Dr P. Marazzi/Science Photo Library CNRI/Science Photo Library CID, ISM/Science
More informationTreatments for allergy are usually straightforward, safe and effective. Common treatments include:
Allergy Medications The treatments prescribed for allergy control the symptoms and reactions; they do not cure the condition. However, using treatments as prescribed can show a huge change in a patient
More informationPsoriasis Guideline 2006 Introduction
Psoriasis Guideline 2006 Introduction This guidance for the management of patients with psoriasis is based on a document first produced as a multi-author BAD document in 1996. Since this time the BAD has
More informationAdditional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
More informationWhat is Psoriasis? Common Areas Affected. Type Who Does it Affect Characteristics
What is? is a term derived from the Greek word psōra which means itch and is a common, long lasting, inflammatory skin condition which affects 1-3% of the UK population and about 80 million people worldwide.
More informationPsoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS
Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS 2 Proudly supported by Disclaimer: Some photographs and models used in this booklet are for illustrative purposes only and
More informationPsoriasis is a skin condition that causes scaly red patches on your skin. There's no cure for psoriasis, but there are treatments that can help.
Patient information from the BMJ Group Psoriasis What is it? What are the symptoms? How is it diagnosed? How common is it? What treatments work? What will happen? Questions to ask Psoriasis If you get
More informationScabies. Care Homes IPC Study Day. Sue Barber Lead Nurse Infection Prevention & Control AV & Chiltern CCG s
Scabies Care Homes IPC Study Day Sue Barber Lead Nurse Infection Prevention & Control AV & Chiltern CCG s Scabies What is it? (warning you will experience itching during this session) Ancient disease evidence
More informationFoam: A Unique Delivery Vehicle for Topically Applied Formulations
: A Unique Delivery Vehicle for Topically Applied Formulations Dov Tamarkin, PhD ix Ltd. Key Words:, Emulsion, Lipophilic Emulsion, Nanoemulsion, Aqueous, Hydroethanolic, Potent-Solvent, Suspension, Ointment,
More informationFor more information, please contact the National Psoriasis Foundation at 800-723-9166 or
For more information, please contact the National Psoriasis Foundation at 800-723-9166 or www.psoriasis.org. PSORIASIS 101: LEARNING TO LIVE IN THE SKIN YOU RE IN is part of an awareness program to educate
More informationAdditional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
More informationPreetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology
International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT
More informationD.RIGOPOULOS, D.IOANNIDES,* D.KALOGEROMITROS, S.GREGORIOU AND A.KATSAMBAS
British Journal of Dermatology 24; 151: 171 175. DOI: 1.1111/j.1365-2133.24.628.x Therapeutics Pimecrolimus cream 1% vs. betamethasone 17-valerate Æ1% cream in the treatment of seborrhoeic dermatitis.
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationTOP TIPS FOR TREATING
TOP TIPS FOR TREATING Sandra Lawton OBE (Nurse Consultant Dermatology and Queen s Nurse, Nottingham University Hospitals NHS Trust) suggests practical ways to manage eczema. Caring for eczema can present
More informationPsoriasis and Sensitive Areas
Psoriasis and Sensitive Areas A positive approach to psoriasis and psoriatic arthritis What are the aims of this leaflet? This leaflet is written to help you understand the most sensitive areas of the
More informationMarch 2011. Management of atopic eczema in primary care. A national clinical guideline. Scottish Intercollegiate Guidelines Network
SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines click here to complete our survey 125 Management of atopic eczema in primary
More informationHydrozole Cream Hydrocortisone (microfine) 1% w/w and Clotrimazole 1% w/w
CONSUMER MEDICINE INFORMATION What is in this leaflet? This leaflet answers some common questions about Hydrozole It does not contain all the available information. It does not take the place of talking
More informationPublic Forum on Psoriasis. 2011 National Series
Public Forum on Psoriasis 2011 National Series Jerry Tan MD FRCPC Schulich School of Medicine and Dentistry, University of Western Ontario Windsor, Ontario, Canada Presented at Caboto Club, Windsor, April
More informationKey words: Psoriasis, Calcipotriol, Tazarotene. tazarotene. 16 ( 4 ) tazarotene calcipotriol ( 22 : 23-34, 2004)
In the treatment of plaque psoriasis, tazarotene was known to be effective, but its efficacy in a Taiwanese population has not been reported. Our purpose was to compare the efficacy, side effects and the
More informationShared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared care protocol for the management of patients with Rheumatoid Arthritis treated with disease modifying antirheumatic drugs (DMARDs)
More informationObstetric Cholestasis (itching liver disorder) Information for parents-to-be
Oxford University Hospitals NHS Trust Obstetric Cholestasis (itching liver disorder) Information for parents-to-be page 2 You have been given this leaflet because you have been diagnosed with (or are suspected
More informationIn Collaboration with Hull And East Yorkshire Hospitals NHS Trust
NHS East Riding of Yorkshire NHS Hull Spot the Difference A Guide to Dermatology In Primary Care In Collaboration with Hull And East Yorkshire Hospitals NHS Trust Contents Introduction 2 Dermatology contact
More informationHitchcock Clinic Manchester, NH. Psoriasis. Overview. Psoriasis 3/9/2009. From heartbreak to heart attack. Mark Quitadamo, MD
Hitchcock Clinic Manchester, NH Psoriasis From heartbreak to heart attack Mark Quitadamo, MD Overview Psoriasis and psoriatic arthritis are common skin and joint disease Psoriasis Unfortunately it is a
More informationYour psoriasis story. Print this out, answer the questions, then share it with your doctor
Your psoriasis story Print this out, answer the questions, then share it with your doctor 1 SYMPTOMS Surface Area Your doctor will use a variety of different factors to measure the severity of your disease,
More informationF r e q u e n t l y A s k e d Q u e s t i o n s
Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationPsoriasis. Student's Name. Institution. Date of Submission
Running head: PSORIASIS Psoriasis Student's Name Institution Date of Submission PSORIASIS 1 Abstract Psoriasis is a non-contagious chronic skin disease that is characterized by inflammatory and multiplying
More informationTOPICAL THERAPY. ADVANTAGES - increased dose of medication to affected area. - reduced systemic side effects and toxicity
TOPICAL THERAPY ADVANTAGES - increased dose of medication to affected area. - reduced systemic side effects and toxicity DISADVANTAGES - takes time - may be greasy or messy - may have different preparations
More informationAcne (Acne Vulgaris) A common type of bacteria that lives on the skin, known as Propionibacterium acnes, sometimes
Acne (Acne Vulgaris) Acne, clinically known as acne vulgaris, is the most common skin disease. It affects 85% of teenagers, some as young as 12, and often continues into adulthood. It is also called pimples,
More informationF REQUENTLY A SKED Q UESTIONS
Acne ogist (a doctor who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. page 1 Q: What is acne? Q: What are the different types of A: Acne is
More informationCase Scenarios. Case Scenario 1 Group A
Case Scenarios Prior to the workshop please work through the following scenario and be prepared to present this to the rest of the group. You can work in groups of 3-4. Specialist nurses, phototherapy
More informationStep 4: Complex and severe depression in adults
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationCommon Skin Conditions in Children. Liz Moore and Emma King Dermatology Nurse Consultants
Common Skin Conditions in Children Liz Moore and Emma King Dermatology Nurse Consultants Diagnosis? Nummular Dermatitis Disc pattern rash (discoid eczema) Clearly demarcated edges Occurs at any age Can
More information1g cream or ointment contains 1 mg methylprednisolone aceponate.
CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will
More informationMEDICATION GUIDE. PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1%
MEDICATION GUIDE PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1% Read the Medication Guide every time you or a family member gets PROTOPIC Ointment. There may be new information. This Medication
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationTopical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement
Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationPsoriasis Can be Cured with Homoeopathy
Homoeopathy Clinic http://www.homoeopathyclinic.com Psoriasis Can be Cured with Homoeopathy Case Report / General Information What you should Know about Psoriasis? It is not a contagious disease. Psoriasis
More informationHow To Deal With The Side Effects Of Radiotherapy
Radiotherapy to the Bowel (Colo-Rectal Tumours) Information for patients Northern Centre for Cancer Care Freeman Hospital Introduction Your oncologist has advised you to have a course of radiotherapy to
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationProtection for hand eczema
Oxford University Hospitals NHS Trust Department of Dermatology Protection for hand eczema Information for patients What can I do to help my hand eczema? Hand eczema (the same as hand dermatitis) is normally
More informationTop 10 Psoriasis Treatment Tips
Top 10 Psoriasis Treatment Tips Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Social Sciences Director, Psoriasis Treatment Center Wake Forest University School of Medicine Winston-Salem,
More informationSPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT ALCOHOL MISUSE
SPECIFICATION FOR THE LOCAL COMMISSIONED SERVICE FOR THE MANAGEMENT OF ALCOHOL MISUSE Date: March 2015 1 1. Introduction Alcohol misuse is a major public health problem in Camden with high rates of hospital
More informationACNE TOP TIPS FOR GPs! Louise Moss GP Moss Valley Medical Practice, Eckington, GPwSI for NDCCG Sept 2013
ACNE TOP TIPS FOR GPs! Louise Moss GP Moss Valley Medical Practice, Eckington, GPwSI for NDCCG Sept 2013 Acne-an important condition Aim for today To have a better understanding of how to treat Acne well,
More informationA Guide to Dermatology in Primary Care. Royal United Hospital Bath NHS Trust
A Guide to Dermatology in Primary Care Royal United Hospital Bath NHS Trust Contents Introduction Clinics, staff & contact details Referral Guidelines on Referral of Benign Lesions Prescribing Information
More informationFor Mild to Moderate Plaque Psoriasis and Moderate to Severe Atopic Dermatitis
For Mild to Moderate Plaque Psoriasis and Moderate to Severe Atopic Dermatitis OLUX-E (clobetasol propionate) Foam, 0.05% Please see Important Safety Information on back page and accompanying Full Prescribing
More informationPeople with Parkinson s sometimes have problems with their skin,
Symptoms and lifestyle Skin and sweating problems in Parkinson's People with Parkinson s sometimes have problems with their skin, and how much or how little they sweat. Some people may only have minor
More informationUCB. Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE
UCB Certolizumab pegol (CIMZIA ) for the treatment of Rheumatoid Arthritis PATIENT ACCESS SCHEME (PAS) SUBMISSION TO NICE July 23 d 2009 1 Executive summary UCB have proposed a patient access scheme (PAS)
More informationGuidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations
More informationInformation for patients receiving short-term hormone treatment and radiotherapy for prostate cancer
Information for patients receiving short-term hormone treatment and radiotherapy for prostate cancer Northern Centre for Cancer Care (NCCC) Freeman Hospital Introduction This leaflet has been written to
More informationSpecialised Services Circular
Specialised Services Circular Issue date: 26 March 2014 ID Category: Status: Public & Press: SSC1417 Request for action N/A Primary Care responsibilities in relation to the prescribing and monitoring of
More informationVersion 2 This guideline describes how to manage patients who are showing signs and symptoms of alcohol withdrawal and Wernicke s Encephalopathy.
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality A Guideline for the Management of Acute Alcohol Withdrawal
More informationGuidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations
More informationStep 2: Recognised depression in adults persistent subthreshold depressive symptoms or mild to moderate depression
Step 2: Recognised depression in adults persistent subthreshold depressive symptoms or mild to moderate depression A NICE pathway brings together all NICE guidance, quality standards and materials to support
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationGuidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma
Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationOxford University Hospitals. NHS Trust. Dermatology Department Frontal Fibrosing Alopecia. Information for patients
Oxford University Hospitals NHS Trust Dermatology Department Frontal Fibrosing Alopecia Information for patients What is Frontal Fibrosing Alopecia (FFA)? FFA is a condition which causes hair loss, mainly
More informationAcne. What causes acne? Formation of Skin Pimples and Acne
Acne Facts & Fixes Acne Acne is the most common skin disease, affecting 85% of Australians aged 15-24 years old. Very few people manage to escape their teenage and young adult years without some pimples
More informationCaring for children and young people with atopic eczema
Royal college of nursing Caring for children and young people with atopic eczema Guidance for nurses This publication is supported by the pharmaceutical industry Caring for children and young people with
More informationA t f e t r e r th t is s lec e t c u t re r e t h t e e st s u t den e t t sh s ould b e e a b a le e t o t :
Dermatopharmacology Prof Werner Sinclair Department of Dermatology University of the Free State Outcomes for this Lecture After this lecture the student should be able to: Name the most important characteristics
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationBRITISH DERMATOLOGICAL NURSING GROUP
Nurse Led systemic monitoring clinics guidance on setting up this service Introduction Nurse led systemic monitoring clinics are an innovative approach to improving care delivery and maintaining both a
More informationMicroSilver BG TM. The innovative agent for beautiful, healthy skin.
The innovative agent for beautiful, healthy skin. Inhalt Why MicroSilver BG TM? 3 What is MicroSilver BG TM? 3 How does MicroSilver BG TM work? 3 Products and usage 4 MicroSilver BG TM still used today
More informationBJD British Journal of Dermatology. Summary SYSTEMATIC REVIEW
SYSTEMATIC REVIEW BJD British Journal of Dermatology Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses E.J. Samarasekera, 1 L. Sawyer, 2 D. Wonderling,
More informationPsoriatic Arthritis. Psoriatic Arthritis 3/05
Psoriatic Arthritis 3/05 Psoriatic Arthritis Arthritis Ireland, 1 Clanwilliam Square, Grand Canal Quay, Dublin 2 T: (01) 661 8188 F: (01) 661 8261 www.arthritisireland.ie What is in this booklet? This
More informationPeninsula Commissioning Priorities Group. Commissioning Policy Varicose Vein Referral
NHS Devon NHS Plymouth Torbay Care Trust Peninsula Commissioning Priorities Group Commissioning Policy Varicose Vein Referral Varicose Vein Referral Guidelines 1. Description of service/treatment Most
More informationGMMMG Interface Prescribing Subgroup. Shared Care Template
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More information21 st CENTURY(December 23, 2008) - "The end of Psoriasis?"
21 st CENTURY(December 23, 2008) - "The end of Psoriasis?" Can you imagine having unattractive-looking dry scales on various parts of your body? You would hardly go for a swim or wear short pants and skirts
More informationHow To Treat Psoriasis With Omega 3 Fatty Acids
CAN PSORIASIS TREATMENT BE AIDED BY OMEGA-3 FATTY ACIDS? Brittney Urban Psoriasis Chronic skin disease Cell life cycle build up Can be disabling Symptoms: Red patches with silvery scales Dry, cracked skin
More informationPSORIASIS. -Multi factorial. -Papulosquamous disorder. -Genetically determined (few) -Chronic Scaly lesions. -Seasonal variations
PSORIASIS -Multi factorial -Papulosquamous disorder -Genetically determined (few) -Chronic Scaly lesions -Seasonal variations -Recurrences & remissions Etiology & Pathogenesis T-cell mediated autoimmune
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More information